10x Genomics Balance Sheet Health
Financial Health criteria checks 6/6
10x Genomics has a total shareholder equity of $724.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $929.7M and $205.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$380.09m |
| Equity | US$724.06m |
| Total liabilities | US$205.61m |
| Total assets | US$929.67m |
Recent financial health updates
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 05We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Recent updates
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 05Financial Position Analysis
Short Term Liabilities: TXG's short term assets ($579.2M) exceed its short term liabilities ($111.0M).
Long Term Liabilities: TXG's short term assets ($579.2M) exceed its long term liabilities ($94.6M).
Debt to Equity History and Analysis
Debt Level: TXG is debt free.
Reducing Debt: TXG has no debt compared to 5 years ago when its debt to equity ratio was 193.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TXG has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 4.4% each year